Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

101. A meta-analysis on intravenous magnesium sulphate for treating acute asthma

A meta-analysis on intravenous magnesium sulphate for treating acute asthma A meta-analysis on intravenous magnesium sulphate for treating acute asthma A meta-analysis on intravenous magnesium sulphate for treating acute asthma Cheuk D K, Chau T C, Lee S L CRD summary This review determined the effectiveness of intravenous magnesium sulphate for preventing the hospitalisation of children with acute asthma. The authors stated that intravenous magnesium sulphate is likely to provide additional (...) benefit in children with moderate to severe acute asthma who are being treated with bronchodilators and steroids. While the authors' conclusion appears to reflect the results presented, the literature search could need updating. Authors' objectives To determine the effectiveness of intravenous magnesium sulphate for preventing the hospitalisation or intensive care unit (ICU) admission of children with acute asthmatic attacks. Searching MEDLINE, EMBASE, the Cochrane Library, the Cochrane CENTRAL

DARE.2005

102. Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis

Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis Alghamdi A A, Al-Radi O O, Latter D A CRD summary This review concluded that giving (...) intravenous magnesium sulphate to people who are undergoing elective coronary artery bypass grafting reduces the risk of post-operative atrial fibrillation. The review was well conducted and the authors' conclusion is likely to be reliable. Authors' objectives The aim was to assess the effects of peri-operative intravenous magnesium sulphate in preventing atrial fibrillation (AF) after coronary artery bypass grafting (CABG). Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register were

DARE.2005

103. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis

Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly S J CRD summary This review assessed the effectiveness of magnesium in preventing post-operative atrial fibrillation (AF) after cardiac surgery. The authors concluded that magnesium (...) administration reduced post-operative AF, but did not significantly alter length of hospital stay or in-hospital mortality. Limitations in the review process, along with variation amongst the included studies, reduce the reliability of the authors' conclusions. Authors' objectives To assess the effectiveness of magnesium for the prevention of post-operative atrial fibrillation (AF) after cardiac surgery. Searching MEDLINE and the Cochrane CENTRAL Register were searched from 1966 to July 2003; the search

DARE.2005

104. Nebulised magnesium in asthma

Nebulised magnesium in asthma BestBets: Nebulised magnesium in asthma Nebulised magnesium in asthma Report By: Craig Ferguson - Clinical Research Fellow Search checked by Marten Howes - SpR Emergency Medicine Institution: Manchester Royal Infirmary Original author: Jonathan Costello Original institution: Royal Preston Hospital Date Submitted: 28th April 2003 Date Completed: 1st September 2004 Last Modified: 21st August 2006 Status: Green (complete) Three Part Question In [an adult with asthma (...) ] is [nebulised beta-agonist with nebulised magnesium sulphate better than nebulsed beta-agonist alone] at [improving airflow and reducing morbidity]? Clinical Scenario A known asthmatic patient is brought into the emergency department with signs consistent with acute asthma. Little improvement is noted with nebulised beta-agonist therapy. You wonder if adjunctive nebulised magnesium sulphate would provide any benefit. Search Strategy Medline 1966-05/04 using the Ovid interface. Repeated August 06 using Ovid

BestBETS2004

105. Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials

Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials Shiga T, Wajima Z I, Inoue T, Ogawa R CRD summary The authors of this review found that prophylactic magnesium given around the time of cardiac surgery reduced (...) the incidence of cardiac arrhythmias, but had no effect on length of hospital stay or mortality. Given the potential for publication and selection bias, and the pooling of diverse results, the conclusions should be treated with caution. Authors' objectives To investigate the effects of prophylactic magnesium given to prevent arrhythmias after cardiac surgery. Searching MEDLINE (1966 to June 2003), EMBASE (1980 to June 2003) and the Cochrane CENTRAL Register (Issue 3 2003) were searched; the search terms

DARE.2004

106. Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation

Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation Coleman C I, Kalus J S, White C M, Spencer A P, Tsikouris J P, Chung J O, Kenyon K W, Ziska M, Kluger J, Reddy P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of ibutilide in the presence and absence of magnesium prophylaxis for the conversion of atrial fibrillation (AF). The mean dose of ibutilide was 2.2 (+/- 1) g. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2004

107. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial.

Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. 14962524 2004 02 13 2004 03 16 2015 06 16 1474-547X 363 9407 2004 Feb 07 Lancet (London, England) Lancet Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. 439-45 Magnesium is neuroprotective in animal models of stroke, and findings of small clinical pilot trials suggest potential benefit in people. We aimed to test whether intravenous (...) magnesium sulphate, given within 12 h of stroke onset, reduces death or disability at 90 days. 2589 patients were randomised within 12h of acute stroke to receive 16 mmol MgSO4 intravenously over 15 min and then 65 mmol over 24 h, or matching placebo. Primary outcome was a global endpoint statistic expressed as the common odds ratio for death or disability at day 90. Secondary outcomes were mortality and death or disability, variously defined as Barthel score less than 95, Barthel score less than 60

Lancet2004

108. Magnesium prophylaxis in cardiac surgery patients

Magnesium prophylaxis in cardiac surgery patients Magnesium prophylaxis in cardiac surgery patients Magnesium prophylaxis in cardiac surgery patients Higgins S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Higgins S. Magnesium prophylaxis in cardiac surgery patients. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2003: 30 Authors' objectives (...) This aim of this report was to assess whether, in patients undergoing cardiac surgery, prophylactic administration of magnesium reduces the incidence of adverse outcomes. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Heart Diseases /surgery; Magnesium; Thoracic Surgery /adverse effects Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton

Health Technology Assessment (HTA) Database.2003

109. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial.

Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. 12826434 2003 06 26 2003 07 17 2015 06 16 1474-547X 361 9375 2003 Jun 21 Lancet (London, England) Lancet Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. 2114-7 Intravenous magnesium can cause bronchodilation in treatment of severe asthma (...) , however its effect by the nebulised route is uncertain. We aimed to assess the effectiveness of isotonic magnesium sulphate as an adjuvant to nebulised salbutamol in severe attacks of asthma. We enrolled 52 patients with severe exacerbations of asthma presenting to the emergency departments at two hospitals in New Zealand. A severe exacerbation was defined as a forced expiratory volume at 1 s (FEV(1)) of less than 50% predicted 30 min after initial administration of 2.5 mg salbutamol via nebulisation

Lancet2003

110. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.

A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. 12540643 2003 01 23 2003 01 27 2013 11 21 1533-4406 348 4 2003 Jan 23 The New England journal of medicine N. Engl. J. Med. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. 304-11 Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia. Nimodipine is a calcium-channel blocker with specific cerebral vasodilator activity. Our objective (...) was to determine whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with severe preeclampsia. We conducted an unblinded, multicenter trial in which 1650 women with severe preeclampsia were randomly assigned to receive either nimodipine (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional protocol) from enrollment until 24 hours post partum. High blood pressure was controlled with intravenous hydralazine as needed

NEJM2003

111. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.

Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. 14645308 2003 12 03 2003 12 11 2016 10 17 1538-3598 290 20 2003 Nov 26 JAMA JAMA Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. 2669-76 Prenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very preterm infants. To determine the effectiveness of magnesium sulfate given for neuroprotection to women at risk (...) to receive a loading infusion of 8 mL (4 g [16 mmol] of 0.5 g/mL of magnesium sulfate solution or isotonic sodium chloride solution [0.9%]) for 20 minutes followed by a maintenance infusion of 2 mL/h for up to 24 hours. Rates of total pediatric mortality, cerebral palsy, and the combined outcome of death or cerebral palsy at a corrected age of 2 years. Data were analyzed for 1047 (99%) 2-year survivors. Total pediatric mortality (13.8% vs 17.1%; relative risk [RR], 0.83; 95% confidence interval [CI

JAMA2003

112. Magnesium sulphate versus phenytoin for eclampsia.

Magnesium sulphate versus phenytoin for eclampsia. BACKGROUND: Eclampsia, the occurrence of a convulsion (fit) in association with pre-eclampsia, remains a rare but serious complication of pregnancy. A number of different anticonvulsants are used to control eclamptic fits and to prevent further convulsions. OBJECTIVES: The objective of this review was to assess the effects of magnesium sulphate compared with phenytoin when used for the care of women with eclampsia. Magnesium sulphate (...) is compared with diazepam and with lytic cocktail in other Cochrane reviews. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth trials register (28 November 2002) and the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2002). SELECTION CRITERIA: Randomised trials comparing magnesium sulphate (intravenous or intramuscular administration) with phenytoin for women with a clinical diagnosis of eclampsia. DATA COLLECTION AND ANALYSIS: Both reviewers assessed trial

Cochrane2003

113. Magnesium sulphate versus diazepam for eclampsia.

Magnesium sulphate versus diazepam for eclampsia. BACKGROUND: Eclampsia, the occurrence of a convulsion in association with pre-eclampsia, remains a rare but serious complication of pregnancy. A number of different anticonvulsants are used to control eclamptic fits and to prevent further fits. OBJECTIVES: The objective of this review was to assess the effects of magnesium sulphate compared with diazepam when used for the care of women with eclampsia. Magnesium sulphate is compared (...) with phenytoin and with lytic cocktail in other Cochrane reviews. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth trials register (28 November 2002) and the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2002). SELECTION CRITERIA: Randomised trials comparing magnesium sulphate (intravenous or intramuscular administration) with diazepam for women with a clinical diagnosis of eclampsia. DATA COLLECTION AND ANALYSIS: Both reviewers assessed and extracted data

Cochrane2003

114. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.

Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. BACKGROUND: Pre-eclampsia is a relatively common complication of pregnancy. Eclampsia, the occurrence of one or more convulsions (fits) in association with the syndrome of pre-eclampsia, is a rare but serious complication. Anticonvulsants are used in the belief they help prevent eclamptic fits and so improve outcome. OBJECTIVES: The objective was to assess the effects of anticonvulsants for pre-eclampsia on the women (...) women) compared magnesium sulphate with placebo or no anticonvulsant. There was more than a halving in the risk of eclampsia associated with magnesium sulphate (relative risk (RR) 0.41, 95% confidence interval (CI) 0.29 to 0.58; number needed to treat (NNT) 100, 95% CI 50 to 100). The risk of dying was non-significantly reduced by 46% for women allocated magnesium sulphate (RR 0.54, 95% CI 0.26 to 1.10). For serious maternal morbidity RR 1.08, 95% CI 0.89 to 1.32. Side effects were more common

Cochrane2003

115. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials

The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials Jee S H, Miller E R, Guallar E, Singh V K, Appel L J, Klag M J Authors' objectives The objectives were to determine whether magnesium supplementation reduces blood-pressure (BP), to (...) identify the dose-response relationship, and to determine trial characteristics associated with the greatest BP reductions. Searching MEDLINE was searched for articles published before May 2001 using the MeSH terms 'magnesium' and 'BP' in clinical trials. The authors also searched the reference lists from original and review articles and reviewed their own reference files. The search was restricted to articles published in English. Study selection Study designs of evaluations included in the review

DARE.2002

116. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. 12057549 2002 06 11 2002 06 19 2016 12 03 0140-6736 359 9321 2002 Jun 01 Lancet (London, England) Lancet Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. 1877-90 Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve (...) outcome. Evidence supported magnesium sulphate as the drug to evaluate. Eligible women (n=10141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. Follow up was until

Lancet2002

117. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial.

Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. 12401244 2002 10 28 2002 11 19 2015 06 16 0140-6736 360 9341 2002 Oct 19 Lancet (London, England) Lancet Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. 1189-96 The benefits of supplemental (...) administration of intravenous magnesium in patients with ST-elevation myocardial infarction (STEMI) are controversial. Despite promising results from work in animals and the ready availability of this simple, inexpensive treatment, conflicting results have been reported in clinical trials. Our aim was to compare short-term mortality in patients with STEMI who received either intravenous magnesium sulphate or placebo. We did a randomised, double-blind trial in 6213 patients with acute STEMI who were assigned

Lancet2002

118. The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis

The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis The use of magnesium sulfate to prevent seizures in the pre-eclamptic gravida: a cost-effectiveness analysis Blackwell S C, Tomlinson M W, Berman S, Redman M E, Hassan S S, Berry S M, Hallak M, Sorokin Y, Cotton D B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of magnesium sulphate (MgSO4) seizure prophylaxis for pre-eclamptic women. MgSO4 therapy was given as a 6.g bolus followed by a 2 g/hour continuous infusion. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2001

119. Nexium (Esomeprazole Magnesium) Delayed-Release Capsules

Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Drug Approval Package: Nexium (Esomeprazole Magnesium) NDA #21-153 & 21-154 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Company: AstraZeneca LP Application No.: 21-153 & 21-154 Approval Date: 2/20/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology

FDA - Drug Approval Package2001

120. Magnesium sulphate versus lytic cocktail for eclampsia.

Magnesium sulphate versus lytic cocktail for eclampsia. BACKGROUND: Eclampsia, the occurrence of a seizure in association with pre-eclampsia, is a rare but serious complication of pregnancy. A number of different anticonvulsants are used to control eclamptic fits and to prevent further seizures. OBJECTIVES: The aim of this review was to compare the effects of magnesium sulphate with those of lytic cocktail when used for the care of women with eclampsia. SEARCH STRATEGY: The register of trials (...) held by the Cochrane Pregnancy and Childbirth Group was searched for relevant trials. The Cochrane Controlled Trials Register in The Cochrane Library Issue 2, 2000 was also searched. SELECTION CRITERIA: Randomised trials recruiting women with eclampsia, and comparing any use of magnesium sulphate with any use of lytic cocktail. DATA COLLECTION AND ANALYSIS: Data were extracted from each report without any blinding of the results or of the treatments which women received. MAIN RESULTS: Two trials

Cochrane2001